US Urological Science

Immune markers for predicting intravesical BCG response

High-grade non-muscle-invasive bladder cancer can recur despite treatment, even when surgery and intravesical therapy are delivered promptly. Intravesical bacillus Calmette-Guérin, commonly called BCG, remains an important option for selected patients at high risk of recurrence or progression. Its effectiveness varies between tumours, partly because each cancer has a distinct immune profile and responds differently to bacterial stimulation. Learn more about Managing Anticoagulation In Patients Undergoing Urologic Surgery.html.

Predicting response to intravesical BCG therapy using tumour immune microenvironment markers could help explain this variation and guide future treatment selection. The goal is not to replace established follow-up with a laboratory result, but to identify biological patterns associated with a sustained response. Tissue, blood and urine samples may eventually provide complementary information, while current treatment decisions must still rely on clinical assessment, cystoscopy, cytology and appropriate imaging.

Why response prediction remains difficult

BCG can provoke a local immune response that promotes antitumour T-cell activity, yet some tumours remain resistant. Dense lymphocyte infiltration, functional CD8-positive T cells and evidence of immune activation may favour response. By contrast, T-cell exclusion, regulatory T cells, suppressive macrophages and checkpoint pathways can create an environment in which BCG has limited effect.

A useful biomarker must distinguish patients who will benefit from BCG from those who simply have a generally aggressive cancer. Stage, grade, tumour size, multifocality, carcinoma in situ, previous recurrence, age and fitness all influence prognosis and treatment choice. A marker associated with poor outcomes may be prognostic without predicting that BCG is ineffective for a particular patient.

Urological Science, published by Elsevier for the Taiwan Urological Association, provides access to original studies, reviews and articles in press. Its bladder-cancer coverage offers a way to assess emerging assays across the full pathway from biological discovery to clinical validation.

What would make an immune biomarker clinically useful

Tumour immune markers are usually measured in tissue obtained during transurethral resection of the bladder tumour. A single biopsy may not represent the whole organ: different lesions can contain different lymphocyte populations, and carcinoma in situ may be present beyond the sampled area. Repeat resection, careful lesion mapping and multiple sampling can therefore improve the quality of the biological dataset.

Immunohistochemistry remains accessible for many pathology laboratories, while multiplex assays can measure CD3-, CD4-, CD8- and FOXP3-positive cells together. Other studies examine PD-1, PD-L1, CTLA-4, granzyme B, perforin, macrophage markers, cytokines, gene-expression scores or the spatial relationship between immune cells and tumour nests. Urinary cytokines, circulating tumour DNA and other less-invasive samples may help when tissue is limited.

Several safeguards would make these findings more useful in practice:

These measures also reduce the risk that an attractive association will disappear when tested in a new population. Patient counselling extends beyond tumour control: surgery for bladder tumours may affect urinary and sexual function, and resources on post-prostate surgery recovery can help frame recovery discussions, although individual advice should come from the treating urologist.

Turning immune signatures into clinical tests

Spatial profiling and single-cell technologies can reveal the cellular communities surrounding a tumour, but complexity does not automatically confer clinical value. A useful test must be reproducible, affordable and feasible within a pathology workflow. Studies should report the assay, specimen handling, cut-off values, missing-data rules and performance in a population independent of the training cohort.

For laboratories in Melbourne, Sydney, Brisbane and other Australian cities, the commercial and regulatory questions are as important as the biology. A laboratory-developed test is not automatically equivalent to a regulated diagnostic, and clinical software used for risk classification may fall within the Australian Therapeutic Goods Administration’s oversight depending on its intended use. Evidence of cost-effectiveness and relevance within Medicare-funded and public hospital pathways is needed before routine testing can be justified.

The test must also fit safely into the treatment pathway. Most patients require tumour resection before BCG is instilled, and anticoagulant management may influence the timing of surgery, haemostasis and subsequent urological care. A practical overview of anticoagulation before surgery illustrates why multidisciplinary planning is especially important for people taking medicines for atrial fibrillation, venous thromboembolism or cardiovascular disease.

Applying evidence across Australian urology

Australian urological care is delivered through public hospitals, private specialists and regional referral networks. Capacity for pathology, repeat cystoscopy and BCG administration varies between services. For people outside major metropolitan centres, travel, accommodation and repeated follow-up appointments can delay assessment or treatment. Telehealth can support discussion and symptom monitoring, although it cannot replace procedures or laboratory investigations.

Documented disparities affecting Aboriginal and Torres Strait Islander communities add an equity dimension to biomarker research. Models trained mainly on metropolitan cohorts may perform less accurately when applied to populations with different disease patterns, access barriers or communication needs. Meaningful validation should therefore include regional centres and Aboriginal Community Controlled Health Services, with community involvement in study design and translation.

Coexisting urinary conditions also belong in the clinical picture. Patients with recurrent stones may have infection, obstruction or additional procedures that complicate symptom assessment and follow-up. The journal’s review of medical stone management advances is a useful reminder that broader urinary health can influence treatment planning. Vaccination history should also be recorded carefully: Australia’s BCG vaccination program is targeted rather than universal, and childhood vaccination is distinct from therapeutic intravesical BCG.

Moving from immune evidence to better care

Current evidence supports evaluating immune markers in well-designed studies, not using them alone to withhold BCG or postpone surveillance. The most credible pathway begins with standardised specimen collection, followed by selection of a limited marker panel, independent validation and prospective assessment of whether biomarker-guided decisions improve recurrence and progression outcomes.

Training cohorts should represent Australia’s diverse populations, while regulatory, ethical and economic review should occur alongside scientific validation. The endpoint should not merely be a statistically significant association. It should be a test that reliably changes management without denying effective therapy to an unsuitable patient.

Readers can use Urological Science’s current and past issues, articles in press, abstracts and open-access reports to follow studies that combine pathology, immunology and clinical outcomes. Share promising findings with urology, pathology and immunology teams, and follow emerging validation studies as they move toward Australian protocols.